Last reviewed · How we verify
Pneumococcal Conjugate Vaccine formulation 1
Pneumococcal Conjugate Vaccine formulation 1 is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 2 development. Also known as: SP0202-IIb.
At a glance
| Generic name | Pneumococcal Conjugate Vaccine formulation 1 |
|---|---|
| Also known as | SP0202-IIb |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
- Irritability
- Injection Site Erythema
- Crying
- Injection Site Pain
- Injection Site Swelling
- Somnolence
- Decreased Appetite
- Pyrexia
- Vomiting
- Nasopharyngitis
- Otitis Media Acute
- Upper Respiratory Tract Infection
Key clinical trials
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- A Study of V118E in Healthy Participants (V118E-003) (PHASE1)
- Clinical Trial of PCV24 in Children Aged 2-17 Years (PHASE1)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001) (PHASE1)
- Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years (PHASE1)
- Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE2)
- A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal Conjugate Vaccine formulation 1 CI brief — competitive landscape report
- Pneumococcal Conjugate Vaccine formulation 1 updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Pneumococcal Conjugate Vaccine formulation 1
What is Pneumococcal Conjugate Vaccine formulation 1?
Pneumococcal Conjugate Vaccine formulation 1 is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Pneumococcal Conjugate Vaccine formulation 1?
Pneumococcal Conjugate Vaccine formulation 1 is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
Is Pneumococcal Conjugate Vaccine formulation 1 also known as anything else?
Pneumococcal Conjugate Vaccine formulation 1 is also known as SP0202-IIb.
What development phase is Pneumococcal Conjugate Vaccine formulation 1 in?
Pneumococcal Conjugate Vaccine formulation 1 is in Phase 2.
What are the side effects of Pneumococcal Conjugate Vaccine formulation 1?
Common side effects of Pneumococcal Conjugate Vaccine formulation 1 include Irritability, Injection Site Erythema, Crying, Injection Site Pain, Injection Site Swelling, Somnolence.
Related
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Also known as: SP0202-IIb
- Compare: Pneumococcal Conjugate Vaccine formulation 1 vs similar drugs
- Pricing: Pneumococcal Conjugate Vaccine formulation 1 cost, discount & access